NY-ESO-1 TCR Engineered T Cells and HSCs (Roswell Park Cancer Institute)

N/A

Report date: 2024/09/21 20:00:09

Base Information

Drug NameNY-ESO-1 TCR Engineered T Cells and HSCs (Roswell Park Cancer Institute)

Drug Alias NameAutologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cellshematopoietic stem cell-derived anti-NY-ESO-1/HLA-DP4 TCR T-cell therapy + anti-NY-ESO-1/HLA-A*0201 TCR T-cell therapy

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy

Mechanisms of ActionAnti-NY-ESO-1T lymphocyte replacementsStem cell replacements

TargetsCancer/testis antigen 1

Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesRoswell Park Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRoswell Park Cancer Institute

Active IndicationsN/A

Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms

Other Information

ATC CodeN/A